The effects of moclobemide on the pharmacokinetics of the 5-HT(1B/1D) agonist rizatriptan in healthy volunteers

AIMS: The new 5-HT(1B/1D) agonist rizatriptan (MK-0462) has recently been registered for the treatment of migraine. Its primary route of metabolism is via monoamine oxidase-A (MAO-A). Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes. Hen...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van Haarst, A D, van Gerven, J M A, Cohen, A F, De Smet, M, Sterrett, A, Birk, K L, Fisher, A L, De Puy, M E, Goldberg, M R, Musson, D G
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 1999
Matèries:
Drug Interactions
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2014288/
https://ncbi.nlm.nih.gov/pubmed/10417495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1046/j.1365-2125.1999.00011.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars